NeuroQure acquires patents for early detection of ASD in newborns using skin biopsy
Click Here to Manage Email Alerts
Key takeaways:
- NeuroQure has acquired the exclusive rights to license patents to detect ASD in newborns using a skin biopsy.
- The patented calcium signaling technique enables early intervention such as behavioral therapy.
A biotech startup that specializes in gene therapy for neurocognitive disorders has acquired the patents to detect autism spectrum disorder in newborns using a skin biopsy, according to a press release.
The patent portfolio comes from the University of California, Irvine, Center for Autism Research and Translation.
Image: Adobe Stock
“The exclusive license of patents from UC Irvine has the potential for NeuroQure to bring medical diagnostic tools validated with top-tier publications and issued patents as a functional biomarker diagnostic for the broad ASD spectrum from the lab to market, enabling early intervention and improving children’s lives,” David Justus, founder and CEO of NeuroQure, said in the release.
Research shows that early diagnosis and treatment of ASD results in better outcomes for the child, according to the release.
The patented calcium signaling technique, which uses a skin biopsy and a functional biophysical assay to detect ASD in newborns, enables early intervention with medically proven therapies such as behavioral therapy.
The patent portfolio offers “parents and physicians a timely and accurate diagnosis that allows for early intervention, and improved outcomes to potentially altering the trajectory of a child’s life,” Justus said.